Comprehensive genomic profiles of small cell lung cancer. |
Authors: |
George, Julie Lim, Jing Shan Jang, Se Jin Cun, Yupeng Ozretić, Luka Kong, Gu Leenders, Frauke Lu, Xin Fernández-Cuesta, Lynnette Bosco, Graziella Müller, Christian Dahmen, Ilona Jahchan, Nadine S Park, Kwon-Sik Yang, Dian Karnezis, Anthony N Vaka, Dedeepya Torres, Angela Wang, Maia Segura Korbel, Jan O Menon, Roopika Chun, Sung-Min Kim, Deokhoon Wilkerson, Matt Hayes, Neil Engelmann, David Pützer, Brigitte Bos, Marc Michels, Sebastian Vlasic, Ignacija Seidel, Danila Pinther, Berit Schaub, Philipp Becker, Christian Altmüller, Janine Yokota, Jun Kohno, Takashi Iwakawa, Reika Tsuta, Koji Noguchi, Masayuki Muley, Thomas Hoffmann, Hans Schnabel, Philipp A Petersen, Iver Chen, Yuan Soltermann, Alex Tischler, Verena Choi, Chang-min Kim, Yong-Hee Massion, Pierre P Zou, Yong Jovanovic, Dragana Kontic, Milica Wright, Gavin M Russell, Prudence A Solomon, Benjamin Koch, Ina Lindner, Michael Muscarella, Lucia A la Torre, Annamaria Field, John K Jakopovic, Marko Knezevic, Jelena Castaños-Vélez, Esmeralda Roz, Luca Pastorino, Ugo Brustugun, Odd-Terje Lund-Iversen, Marius Thunnissen, Erik Köhler, Jens Schuler, Martin Botling, Johan Sandelin, Martin Sanchez-Cespedes, Montserrat Salvesen, Helga B Achter, Viktor Lang, Ulrich Bogus, Magdalena Schneider, Peter M Zander, Thomas Ansén, Sascha Hallek, Michael Wolf, Jürgen Vingron, Martin Yatabe, Yasushi Travis, William D Nürnberg, Peter Reinhardt, Christian Perner, Sven Heukamp, Lukas Büttner, Reinhard Haas, Stefan A Brambilla, Elisabeth Peifer, Martin Sage, Julien Thomas, Roman K
|
Citation: |
George J, etal., Nature. 2015 Aug 6;524(7563):47-53. doi: 10.1038/nature14664. Epub 2015 Jul 13. |
RGD ID: |
151347582 |
Pubmed: |
PMID:26168399 (View Abstract at PubMed) |
PMCID: |
PMC4861069 (View Article at PubMed Central) |
DOI: |
DOI:10.1038/nature14664 (Journal Full-text) |
We have sequenced the genomes of 110 small cell lung cancers (SCLC), one of the deadliest human cancers. In nearly all the tumours analysed we found bi-allelic inactivation of TP53 and RB1, sometimes by complex genomic rearrangements. Two tumours with wild-type RB1 had evidence of chromothripsis leading to overexpression of cyclin D1 (encoded by the CCND1 gene), revealing an alternative mechanism of Rb1 deregulation. Thus, loss of the tumour suppressors TP53 and RB1 is obligatory in SCLC. We discovered somatic genomic rearrangements of TP73 that create an oncogenic version of this gene, TP73Δex2/3. In rare cases, SCLC tumours exhibited kinase gene mutations, providing a possible therapeutic opportunity for individual patients. Finally, we observed inactivating mutations in NOTCH family genes in 25% of human SCLC. Accordingly, activation of Notch signalling in a pre-clinical SCLC mouse model strikingly reduced the number of tumours and extended the survival of the mutant mice. Furthermore, neuroendocrine gene expression was abrogated by Notch activity in SCLC cells. This first comprehensive study of somatic genome alterations in SCLC uncovers several key biological processes and identifies candidate therapeutic targets in this highly lethal form of cancer.
|
|